HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 06, June 2017 – Advocacies in Support of Rare Disease Patients       » Bayer and NUS Enterprise Announce Winners of Grants4Apps? Singapore Open Innovation Challenge       » Cancer Control Efforts in Vietnam: Interview with Dr Tran Thanh Huong       » China Sets up National Lab Developing Brain-Like AI Technology       » New Womb-Like Invention for Preterm Infants       » World Asthma Day: Managing and Living with Asthma       » Managing Liver Cancer as a Global Health Problem      
EYE ON CHINA
Lilly and Novast expand state of the art manufacturing facility in Nantong, China

Lilly and Novast Laboratories Ltd. have commenced the expansion of manufacturing and development facility capacities in Nantong, Jiangsu, China. The expansion is a result of Lilly's strategic partnership signed in 2012 with Novast to create a platform of Lilly-branded generic medicines. The facility will be located on a 22-acre campus located inside the Free Trade Zone of the Nantong Economic Technology Development Area (NETDA). The upcoming facility will be built employing a quality by design approach, designed by the world's leading engineering consultants and is a direct culmination of a synergistic teamwork between Lilly and Novast personnel. The facility will be state of the art and world class with emphasis on total quality and safety at each step of the design process.

"This day marks a new chapter for Novast as we are transitioning from commercializing quality prescription products in the United States to focusing on catering the same to the China domestic needs through the collaboration platform with Lilly," said Dr. Zhang, President and CEO of Novast Holdings, Ltd.

"We are delighted to see the facility expansion of Novast under the strategic partnership of Lilly-Novast on brand-generic medicine. In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline, as well as select Lilly-branded generic medicines that meet Lilly Global Quality Standards. The additional manufacturing capabilities provided by Novast will allow us to better deliver on that strategy," commented Mr. Alfonso Zulueta, Sr. Vice President and President of Emerging Markets, Eli Lilly and Company.

The expansion will involve the addition of a 260,000 square foot manufacturing facility, enabling the production of both sustained release and containment solid oral dosage prescription pharmaceuticals with an annual additional capacity of more than 2.2 billion units. The company plans to invest 60-70 million US dollars and is anticipated to complete construction by the end of 2015. When the facility becomes fully operational it will not only provide quality products benefiting patients, but also help the local economy in the creation of more than 350 highly skilled additional jobs. "As an expat living and working in the Nantong area for the past 8 years I am extremely impressed and grateful to NETDA and Nantong Municipal Government for their never-ending support and continued cooperation during all these years," commented Prasad Pinnamaraju, Senior Vice President and COO of Novast Holdings, Ltd.

Mr. Andrew Hodge, President of Lilly China, indicated that the expanded manufacturing facilities in Novast will impose a strong support to Lilly China's full value chain strategy, which is an integration of business presence including Lilly-owned manufacturing, sales and marketing, R&D and branded generics.

Source: PR Newswire

Click here for the complete issue.

NEWS CRUNCH  
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy